Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 0.46 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | VCP | P55072 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.32 |
| ▸ | PLEC | Q15149 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5064580 | 0.89 | CNR1 (0.53) | CNR1CNR2NISCHMTORADK | |
| SCHEMBL14206968 | 0.85 | CNR1 (0.40) | CNR1CNR2NISCHMTORADK | |
| SCHEMBL14043756 | 0.76 | PLEC (0.42) | CNR1NISCHMTORADKPLEC | |
| SCHEMBL2049365 | 0.72 | NISCH (0.52) | NISCHMTORADKCASP6 | |
| SCHEMBL13808032 | 0.70 | CNR1 (0.72) | CNR1CNR2 | |
| SCHEMBL14206110 | 0.70 | CNR1 (0.53) | CNR1CNR2DRD2PLEC | |
| SCHEMBL13808030 | 0.70 | CNR1 (0.65) | CNR1CNR2PLEC | |
| SCHEMBL13807927 | 0.69 | CNR1 (0.57) | CNR1CNR2PLEC | |
| SCHEMBL14043755 | 0.69 | CNR1 (0.50) | CNR1CNR2DRD2PLEC | |
| SCHEMBL771236 | 0.68 | NISCH (0.64) | NISCHMTORADKOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| US-20070105819-A1 | CB-1 modulating compounds and their use | ACADIA PHARMACEUTICALS, INC. | 2007-05-10 | — | — | US | disclosed |
| WO-2007047737-A1 | CB-1 MODULATING COMPOUNDS AND THEIR USE | ACADIA PHARMACEUTICALS INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105819-A1 | CB-1 modulating compounds and their use | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885NISCH 3697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.